IBRX Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against ImmunityBio, Inc.

Core Viewpoint - A class action lawsuit has been filed against ImmunityBio, Inc. for allegedly misleading investors about its lead product, Anktiva, during the specified class period from January 19, 2026, to March 25, 2026 [1][2]. Allegations - The complaint claims that Soon-Shiong, a defendant in the case, materially overstated the capabilities of Anktiva, which is intended for treating a specific type of bladder cancer [2]. - A warning letter from the U.S. Food and Drug Administration (FDA) was publicized on March 24, 2026, indicating that promotional communications created a misleading impression that Anktiva could cure and prevent all cancers [3]. Market Impact - Following the release of the FDA warning letter, ImmunityBio's stock price fell by $1.98 per share, representing a 21% decline, closing at $7.42 per share on March 24, 2026 [3]. Class Action Participation - Shareholders interested in serving as lead plaintiffs must submit their papers to the court by May 26, 2026. Participation in the case is not required to be eligible for recovery [4]. Legal Representation - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses for representation [5].